Literature DB >> 26663699

Repeated Contrast Administration Is Associated With Low Risk of Postcontrast Acute Kidney Injury and Long-Term Complications in Patients With Severe Chronic Kidney Disease.

S Winther1,2, M Svensson3, H S Jørgensen3, H Birn3,4, H E Bøtker1, P Ivarsen3, M Bøttcher2.   

Abstract

Patients with chronic kidney disease (CKD) frequently require radiographic examinations. We investigated the impact of repeated contrast administrations on short- and long-term kidney function and mortality in kidney transplantation candidates. In a prospective study, 81 predialysis transplantation candidates underwent computed tomography angiography (CTA) and invasive coronary angiography (ICA) as part of a pretransplant cardiovascular evaluation. Postcontrast plasma creatinine (P-creatinine) changes were compared with a precontrast control period. We identified postcontrast acute kidney injury (AKI) in 10 patients (13%) after CTA and in two patients (3%) after ICA. Compared with the control period, relative changes in P-creatinine were significantly higher after CTA (p < 0.001) and ICA (p < 0.01). Diabetic kidney failure (p < 0.05) and contrast dose >0.8 mL/kg (p < 0.001) were associated with increases in P-creatinine. All cases of postcontrast AKI were reversible, and we found no differences between the progression rates of the kidney failure during 12 months before and after contrast exposure (p = 0.56). In a Cox regression analysis, creatinine changes after CTA or ICA were not associated with increased need for dialysis treatment or mortality. Contrast exposure and transient postcontrast AKI did not increase the risk of accelerated CKD progression or the time to initiation of dialysis or death. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research; practice

Mesh:

Substances:

Year:  2015        PMID: 26663699     DOI: 10.1111/ajt.13545

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Analysis of the association between emergency dialysis start in patients with end-stage kidney disease and non-steroidal anti-inflammatory drugs, proton-pump inhibitors, and iodinated contrast agents.

Authors:  Aurélie Pétureau; Maxime Raffray; Elisabeth Polard; Cécile Couchoud; Cécile Vigneau; Sahar Bayat
Journal:  J Nephrol       Date:  2021-04-20       Impact factor: 3.902

2.  Acute kidney injury in renal transplant recipients undergoing cardiac surgery.

Authors:  Gregory L Hundemer; Anand Srivastava; Kirolos A Jacob; Neeraja Krishnasamudram; Salman Ahmed; Emily Boerger; Shreyak Sharma; Kapil K Pokharel; Sameer A Hirji; Marc Pelletier; Kassem Safa; Win Kulvichit; John A Kellum; Leonardo V Riella; David E Leaf
Journal:  Nephrol Dial Transplant       Date:  2021-01-01       Impact factor: 5.992

3.  Coronary Computed Tomography Angiography in Diagnosing Obstructive Coronary Artery Disease in Patients with Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Xingxing S Cheng; Suman Mohanty; Valery Turner; Domenico Mastrodicasa; Simon Winther; Dominik Fleischmann; Jane C Tan; William F Fearon
Journal:  Cardiorenal Med       Date:  2020-12-15       Impact factor: 4.360

Review 4.  Iodinated contrast medium: Is there a re(n)al problem? A clinical vignette-based review.

Authors:  Karim Lakhal; Stephan Ehrmann; Vincent Robert-Edan
Journal:  Crit Care       Date:  2020-11-10       Impact factor: 9.097

5.  A risk scoring model to predict renal progression associated with postcontrast acute kidney injury in chronic kidney disease patients.

Authors:  Seung Don Baek; So Mi Kim; Jae-Young Kang; Minkyu Han; Eun Kyoung Lee; Jai Won Chang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

6.  Does Exposure to Computed Tomography Contrast Media Increase Risk of End-Stage Renal Disease?

Authors:  Eunsoo Lim; Jong-Hwan Jang; Dukyong Yoon; Young-Gi Min; Hyuk-Hoon Kim
Journal:  Med Sci Monit       Date:  2020-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.